TODO: Skip to main content
Top
Gepubliceerd in:

01-08-2007 | Original Paper

Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis

Auteurs: Dinesh Khanna, Daniel E. Furst, Weng Kee Wong, Joel Tsevat, Philip J. Clements, Grace S. Park, Arnold E. Postlethwaite, Mansoor Ahmed, Shaari Ginsburg, Ron D. Hays, for the Scleroderma Collagen Type 1 Study Group

Gepubliceerd in: Quality of Life Research | Uitgave 6/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

ObjectivesTo evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures—the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods We assessed the test–retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors—the SF-36 change in health item (patients who answered “somewhat better” formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test–retest reliability for the SF-6D was high (ICC = 0.82 [95% CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16–0.52). The MID estimate for the SF-6D using the change in SF-36 item −0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
Auteurs
Dinesh Khanna
Daniel E. Furst
Weng Kee Wong
Joel Tsevat
Philip J. Clements
Grace S. Park
Arnold E. Postlethwaite
Mansoor Ahmed
Shaari Ginsburg
Ron D. Hays
for the Scleroderma Collagen Type 1 Study Group
Publicatiedatum
01-08-2007
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 6/2007
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-007-9207-3